Clinical Trials Logo

Filter by:
  • Suspended  
  • « Prev · Page [2]
NCT ID: NCT00708825 Suspended - Clinical trials for Blood Vessel Prosthesis

Reverse-Loop Upper Arm Arteriovenous Graft

Start date: January 2008
Phase: N/A
Study type: Observational

Background: A conventional configured prosthetic arteriovenous graft (AVG) usually wastes most upper arm vessels that a reverse-loop design may conserve. This study examined the feasibility of the AVG construction and its outcome. Methods: Retrospective review of clinical outcomes of reverse-loop upper arm AVG patients. Measures included hemodialysis function, duplex scan, procedural complications, and follow-up interventions

NCT ID: NCT00190034 Suspended - Clinical trials for Cardiovascular Disease

Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether N-acetylcysteine is effective in the prophylaxis of post-cardiopulmonary bypass acute renal impairment.

NCT ID: NCT00172497 Suspended - Schizophrenia Clinical Trials

Aggressive Acts Among Patients With Schizophrenia

Start date: August 2001
Phase: N/A
Study type: Observational

The purpose of this series of study has a many-fold intention depicted as follows: to describe and characterize schizophrenic patients' aggressive acts in hospital and community, to identify and specify heterogeneity in their structure, and to look for and set up risk factors for prevention. This study investigates four major issues: (1) Establishing an objective behavior rating scale for measuring aggressive acts; (2) Understanding the characteristics and incidence of aggressive acts by patients with schizophrenia; (3) Exploration of the heterogeneous structure of aggressive acts by patients with schizophrenia; and (4) Identifying the risk factors of aggressive acts of patients with schizophrenia.

NCT ID: NCT00166803 Suspended - Clinical trials for Diabetes Mellitus, Atherosclerosis

The Impact of Rosiglitazone on Regression of Atherosclerosis

Start date: June 2005
Phase: N/A
Study type: Interventional

Cardiovascular events are the leading cause of death in developed countries worldwide, including Taiwan. The disruption of atherosclerotic plaques and the subsequent formation of thrombi are currently recognized as the major cause of morbidity and mortality of cardiovascular diseases. Therefore, early detection of vulnerable plaques is clinically important for risk stratification and also to provide early treatment. Several imaging approaches have been adapted to detect vulnerable plaques, however, most of them are based on morphologic characteristics of atheroma. We hypothesize that PPARĪ³-induced plaque regression could be monitored clinically by use of 18FDG PET/CT approach, which could assess the inflammatory activity, and can be detected noninvasively earlier than previously reported.